|Mr. Timothy W. Trost||Sr. VP, CFO & Corp. Sec.||504.39k||N/A||1958|
|Dr. William Garrett Nichols M.D., MS||Chief Medical Officer||584.87k||N/A||1969|
|Dr. Roy W. Ware Ph.D., MBA||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
|Dr. Randall Lanier Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Mr. Joseph F. Rutledge||VP of Information Technology & Chief Information Officer||N/A||N/A||N/A|
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 8.